Sign in to view content

Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD

Neil M. Bressler, MD

Video
Published 2022

Related

Episode 13: Long-Term Treatment of Wet AMD by 50+ Anti-VEGF Injections with Dr. Sean Adrean
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Pentosan Polysulfate Maculopathy Versus Age-Related Macular Degeneration: Comparative Assessment With Multimodal Imaging
Joseph S Christiansen, MD
Annual Meeting Talks
2020
Brolucizumab for the Treatment of Visual Impairment Due to Diabetic Macular Edema: 52-Week Results From the KESTREL and KITE Studies
David M. Brown, MD
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more